NSD2 and hematopoietic and lymphoid cell neoplasm: As expected, hematologic cancers harboring activating NSD2 mutations emerged as the most sensitive to treatment with LLC0150 (IC50 ranging from 0.274 - 69.68 nM), which was immediately followed by AR-positive PCa cell lines (shown in red, Fig. 4i).